| Current Price | $7.35 | Mkt Cap | $35.8M |
|---|---|---|---|
| Open | $8.86 | P/E Ratio | 0.00 |
| Prev. Close | $7.35 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $7.15 - $9.02 | Volume | 1,040,795 |
| 52-Wk Range | $3.12 - $19.25 | Avg. Daily Vol. | 655,325 |
A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
| Current Price | $7.35 | Mkt Cap | $35.8M |
|---|---|---|---|
| Open | $8.86 | P/E Ratio | 0.00 |
| Prev. Close | $7.35 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $7.15 - $9.02 | Volume | 1,040,795 |
| 52-Wk Range | $3.12 - $19.25 | Avg. Daily Vol. | 655,325 |
The best Bull and Bear pitches based on recency and number of recommendations.
My God, is the SEAMLESS trial still running? This pointless excursion began all the way back at the beginning of 2011 and is still lumbering along despite failing an interim futility analysis in December 2014. That's right! The trial already failed.… More
In the last few months, lots of weak biopharmas took huge hits on negative catalysts and their share prices seemed to gravitate towards the 50 cent level with market caps at about half of cash on hand. I owned substantial chunks of almost all of them… More
Read the most recent pitches from players about CYCC.
Recs
oscillation
(81.38)
Submitted: 6/1/2015 1:40:33 AM :
Start Price:
$8.64
NASDAQ:CYCC Score:
-92.17
nev
Recs
UnstableEnabled
(< 20)
Submitted: 12/21/2013 3:30:17 AM :
Start Price:
$44.94
NASDAQ:CYCC Score:
-189.61
A boatload of good news will come Cyclacel's way in Q1 2014. (SEAMLESS) will continue successfully passing it's mid-point futility review at which time a partnership with big-pharma to fund an MDS Phase 3 trial will likely come to fruition.
It's entirely possible that other p.p.s. accelerators like accelerated approval and a SPA agreement with the FDA involving sapacitabine in MDS will advance the stock as well.
Sorely depressed, any good new will cause the stock to surge upward.
Recs
toegar2000
(37.98)
Submitted: 3/2/2013 10:25:20 AM :
Start Price:
$64.19
NASDAQ:CYCC Score:
-236.11
Looks good IMO
Find the members with the highest scoring picks in CYCC.
BravoBevo (99.98) Score: +1,220.77
Put on a coat before answering the door. If it's someone you know, let them know you just got home; for everyone else, tell them you're leaving.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| BravoBevo | 99.98 | 3/10/2020 |
|
5Y | $0.50 | +1,370.00% | +34.42% | +1,335.58 | 0 Comment | |
| portefeuille2 | 99.33 | 4/29/2019 |
|
5Y | $0.68 | +973.62% | +28.00% | +945.62 | 0 Comment | |
| Momentum21 | 86.89 | 3/1/2018 |
|
5Y | $1.52 | +382.25% | +38.56% | +343.69 | 0 Comment | |
| longtermgrowth09 | < 20 | 8/3/2010 |
|
5Y | $137.26 | -94.65% | +234.01% | +328.66 | 0 Comment | |
| mrtofoo | 30.48 | 1/7/2008 |
|
5Y | $425.66 | -98.27% | +178.12% | +276.39 | 0 Comment | |
| MotleyMK | 51.60 | 7/20/2017 |
|
5Y | $1.73 | +324.86% | +52.26% | +272.60 | 0 Comment | |
|
VisionThing | < 20 | 7/19/2017 |
|
1Y | $1.76 | +317.38% | +52.21% | +265.17 | 0 Comment |
| imrhh | < 20 | 5/7/2007 |
|
3M | $637.27 | -98.85% | +163.25% | +262.10 | 2 Comments | |
| bluebare | 31.08 | 12/7/2012 |
|
5Y | $75.63 | -90.28% | +164.54% | +254.82 | 0 Comment | |
| klaracat | 31.00 | 10/22/2012 |
|
5Y | $60.93 | -87.94% | +162.45% | +250.39 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
